Hook / Thesis
Telix Pharmaceuticals put up a tidy Q1: group revenue of $230 million, Precision Medicine revenue of $186 million, and a reaffirmed FY 2026 revenue range of $950-970 million. That combination - accelerating commercial sales plus meaningful late-stage progress in both prostate therapeutics (TLX591-Tx) and brain imaging (TLX101-Px) - gives the stock a near-term narrative runway that a disciplined swing trade can exploit.
Technically the tape looks constructive: price near $9.95, moving averages trending higher, RSI elevated but not extreme, and MACD showing bullish momentum. At the same time, short selling and heavy short volume have been a recurring feature, meaning positive data or continued revenue momentum could prompt quick squeezes. My trade idea: take a controlled long with an entry at $9.95, a stop at $8.25, and a target of $15.00, sized so the stop limits the downside and allows the company’s fundamental drivers to play out over the mid term.
What the company does and why the market should care
Telix is a nuclear medicine company focused on radiopharmaceuticals for oncology. The business is organized across Commercial and Product Development segments. The commercial portfolio includes approved imaging agents (Illuccix and Gozellix) and a growing distribution network; the product development pipeline contains late-stage oncology assets such as TLX591-Tx (a lutetium-177 PSMA therapeutic for prostate cancer) and TLX101-Px (Pixclara), a targeted amino acid PET imaging agent for glioma.
The market cares because Telix sits at the intersection of two high-growth radiopharma markets: PSMA-targeted prostate cancer therapeutics and advanced PET imaging for brain tumors. Those markets are capital efficient compared with large molecule oncology drugs, and approval / reimbursement success can translate into rapid revenue scaling. The Q1 print and guidance reaffirmation indicate commercial traction, while clinical and regulatory milestones provide discrete upside catalysts that are easy for investors to track.
Data-backed support for the thesis
- Q1 2026 unaudited group revenue: $230 million - up 11% quarter-over-quarter.
- Precision Medicine revenue: $186 million - up 16% quarter-over-quarter, indicating that the imaging/therapeutics franchises are driving growth inside the commercial business.
- Company reaffirmed FY 2026 revenue guidance of $950-970 million, implying continued top-line momentum versus the run rate in Q1.
- Clinical & regulatory progress: Part 1 of the ProstACT Phase 3 for TLX591-Tx achieved primary objectives (acceptable safety/tolerability across 36 dosed patients), and the company resubmitted an NDA for TLX101-Px (Pixclara) for brain cancer imaging after addressing an earlier Complete Response Letter.
- Market snapshot: current price ~$9.95 with market capitalization roughly $3.37 billion. 52-week range: high $20.00 (04/24/2025), low $6.28 (02/17/2026).
- Technicals: 10-day SMA $9.264, 20-day SMA $8.796, 50-day SMA $7.812; 9-day EMA $9.316 and 21-day EMA $8.806. RSI is ~69.6 and MACD indicates bullish momentum.
- Short interest and short volume: frequent elevated short volume days and short interest data show days-to-cover around 1 day historically - that dynamic can accelerate moves on positive news.
Valuation framing
Using the midpoint of FY 2026 guidance ($960 million) against the current market cap of approximately $3.37 billion gives a market-cap-to-revenue multiple of ~3.5x. That multiple sits in a middle ground: not cheap for a company that is still unprofitable (trailing P/E is negative), but not stratospheric for a commercial-stage specialty biotech with meaningful recurring revenue and multiple late-stage assets.
Important context: the reported P/E is deeply negative (company is loss-making), and the price-to-book is elevated (PB ~7.85). These figures reflect prior investment into R&D and commercialization, and indicate the stock still carries growth expectations rather than value innings. In short, valuation is logical only if Telix continues 2026 revenue execution, converts late-stage programs to approvals, or shows meaningful margin expansion.
Catalysts to watch (timeline-sensitive)
- Regulatory timing on the TLX101-Px NDA resubmission - any FDA action or communication is a clear binary catalyst.
- Progress on ProstACT Part 2 and the IND amendment submission/presentation to the FDA - downstream data releases or expansion into the U.S. trial program are material.
- Quarterly revenue prints and updates to FY 2026 guidance - continued beats would validate the 3-4x revenue multiple.
- Commercial traction of Illuccix and Gozellix and uptake metrics from the company’s radiopharmacy network; sales momentum or widening adoption would provide steady upside.
- Corporate governance change: appointment of David Gill as Non-Executive Director and planned transition to Chair (effective 05/11/2026) - could improve execution and capital markets access.
Trade plan (actionable)
Position: Long TLX
Entry price: $9.95
Stop loss: $8.25
Target: $15.00
Horizon: mid term (45 trading days) - this trade is designed to capture a combination of continued commercial momentum and at least one clinical/regulatory catalyst. I prefer 45 trading days because it allows time for interim regulatory communications, traction reports from the commercial channel, and any near-term presentations or filings to register with the market.
Size and risk control: position size should be set so that the maximum loss to the portfolio if the stop is hit is within your pre-determined risk tolerance (for many retail traders, 1-2% of portfolio risk). Use the stop at $8.25 to limit downside to roughly 17% from entry while leaving enough room for normal intraday volatility.
Trade management: If Telix prints another quarter that beats guidance or if the FDA signals acceptance of the TLX101-Px resubmission, consider taking partial profits at $12.50 and let remaining exposure run toward $15.00. If the company misses revenue expectations or guidance is withdrawn, tighten stops or exit entirely - this trade is catalyst-driven and should not be held through a material negative revision.
Key upside scenarios
- FDA accepts the TLX101-Px resubmission without further major questions - creates immediate rerating potential for an imaging asset with orphan and fast-track advantages.
- Clinical progress in ProstACT Part 2 or rapid expansion of the therapeutic program into U.S. cohorts - validates the TLX591 therapeutic pathway and expands addressable market.
- Consistent commercial execution that sustains the FY26 revenue range or prompts upward guidance - supports the 3.5x market-cap-to-revenue multiple and allows the stock to re-test higher levels toward the 52-week high.
Risks and counterarguments
At least four risks to keep front-of-mind:
- Regulatory risk: Resubmitted NDAs can still face additional questions or require more data. Any delay or another Complete Response Letter would be material and could compress the multiple quickly.
- Commercial adoption risk: Revenue growth depends on payer coverage and clinician uptake for imaging agents and therapeutics. Slower-than-expected reimbursement or adoption curves would pressure top-line growth and upside potential.
- Legal / litigation risk: There is an existing class action filing related to alleged misstatements on past prostate therapeutic progress. Continued litigation or adverse rulings could distract management and increase financial exposure.
- Execution and manufacturing risk: Radiopharmaceuticals require complex supply chains and quality control. Any supply disruptions, manufacturing non-conformances, or distribution issues at the company’s radiopharmacy network could impair sales and margins.
- Market structure / shorting volatility: Elevated short volume and concentrated short interest make TLX prone to sudden spikes and fast reversals. That can work to the upside in a bullish scenario, but it can also create abrupt downside if shorts pile on around a negative catalyst.
Counterargument
One reasonable counterargument is that the stock is already priced for perfection. The market-cap-to-revenue multiple (about 3.5x on FY26 midpoint) requires continued flawless execution: sustained revenue growth, successful regulatory outcomes, and margin improvement. With a negative P/E and elevated PB ratio, any hiccup could trigger outsized downside. The class action suit and history of prior regulatory feedback increase the path-dependent risk - investors may prefer to wait for further binary outcomes before committing substantial capital.
Why I still like the trade
I view the current setup as a defined-risk, asymmetric opportunity. The company has demonstrable commercial fuel - $230M in Q1 revenue and a near-$1B revenue run rate target for FY26 - and late-stage assets that, if favorable, are high-impact. That combination gives positive catalysts traction. Setting a clear stop at $8.25 limits downside while the target of $15.00 references both the prior leader levels and a reasonable re-rating if one or more catalysts come through.
What would change my mind
I would reduce or exit exposure if the company: misses Q2 (or interim) revenue expectations, withdraws or further delays the TLX101-Px NDA, reveals manufacturing problems at scale, or if material negative findings emerge from ProstACT Part 2. Conversely, an FDA acceptance of TLX101-Px or clear approval pathway signals for TLX591-Tx would encourage adding to the position and extending the target upward.
Bottom line
Telix’s Q1 print and regulatory progress create a near-term narrative and measurable catalysts. For traders comfortable with biotech/regulatory risk, a defined long at $9.95 with a stop at $8.25 and a target of $15.00 over a mid-term window (45 trading days) balances risk and reward. Keep position sizing conservative and be prepared to act quickly on data or guidance revisions - this is a catalyst-driven, event-rich trade rather than a passive buy-and-hold.